ROIV
HealthcareRoivant Sciences Ltd.
$21.30
$-0.63 (-2.87%)
Jan 5, 2026
Price History (1Y)
Analysis
Roivant Sciences Ltd. is a biotechnology company in the healthcare sector with a significant market presence. The company operates within the biotechnology industry and has a substantial scale, boasting a market capitalization of $14.81B, revenue of $20.33M (TTM), and approximately 750 employees. The financial health of Roivant Sciences Ltd. is characterized by negative profitability metrics. The company reported a gross margin of 0.0%, operating margin of -18595.4%, and profit margin of 0.0%. Additionally, the company's net income was -$700,988,032 (TTM), with an EBITDA of -$1,108,375,040. Its returns on equity and assets were also negative at -17.4% and -12.4%, respectively. The balance sheet reveals a significant amount of cash on hand at $4.39B, but a relatively small debt load of $98.85M, resulting in a debt-to-equity ratio of 2.06. Roivant Sciences Ltd.'s valuation context is marked by a negative forward P/E ratio of -18.81 and an EV/EBITDA of -10.29. The company's revenue growth has been declining at a rate of -64.9% (YoY), while its earnings growth is not available. The 52-week high price was $23.47, while the low was $8.73, with a beta of 1.22 indicating moderate volatility relative to the market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Visit website →Key Statistics
- Market Cap
- $14.81B
- P/E Ratio
- N/A
- 52-Week High
- $23.47
- 52-Week Low
- $8.73
- Avg Volume
- 8.00M
- Beta
- 1.22
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United Kingdom
- Employees
- 750